Study of three drugs for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of three drugs (SHR-A2102, Adebrelimab, and SHR-8068) for people with advanced non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink or slow the growth of the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have confirmed non-small cell lung cancer that is advanced or has spread to nearby areas and cannot be removed by surgery.
- You need to have at least one tumor that can be measured on a scan.
- You should be between 18 and 70 years old.
- Your general health must be good enough to perform light activities (like walking or light housework) without help.
- You cannot have active or untreated brain metastases, other cancers, uncontrolled fluid buildup in the belly or lungs, or severe heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.
This trial tests a combination of two new drugs (SHR-A1811 and AK112) for people with a specific type of advanced lung cancer that has changes in the HER2 gene. It may help those whose cancer has gotten worse after one previous treatment, or who have not yet had any treatment for advanced disease.
This trial tests a new drug, SHR-1826, for people with advanced or metastatic non-small cell lung cancer that has gotten worse after previous treatment. The goal is to see if the drug can help control the cancer.
This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.
This early-phase trial tests an injectable cancer drug (SHR-A1811) given with either pyrotinib or another targeted drug (SHR-1316) in people with advanced lung cancer. The goal is to see how safe the combination is and how well it can control the cancer.
This trial tests a new drug SHR-A2102 combined with other treatments for advanced or metastatic breast cancer. It aims to see if the combination is safe and effective.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.